Skip to content

Study · Non-randomized trial · 2016

10 results

Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials.

Geiser JS, Heathman MA, Cui X, Martin J, Loghin C, Chien JY, de la Peña A

Clinical pharmacokinetics1 May 2016Cited by 81 (Europe PMC)

PMID26507721 (opens in a new tab)DOI10.1007/s40262-015-0338-3 (opens in a new tab)PepBankPUB-26507721
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanNon-randomized trialPharmacokinetics

    In patients with T2D and healthy subjects, dulaglutide reached maximum concentration in 48 h.

    In plain wordsIn people with diabetes and healthy people, dulaglutide reached its highest concentration in 48 hours.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableTime to maximum concentration
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    Time to maximum concentration
    48 h
    dulaglutide

    Source sentences

    Summary
    Dulaglutide gradually reached the maximum concentration in 48 h and had a terminal elimination half-life of 5 days.
    1 context sentence
    Summary · context
    The clinical pharmacokinetics of dulaglutide were characterized in patients with T2D and healthy subjects.MethodsThe pharmacokinetics of dulaglutide were assessed throughout clinical development, including conventional pharmacokinetic analysis in clinical pharmacology studies and population…
  2. 02HumanNon-randomized trialPharmacokinetics

    In patients with T2D and healthy subjects, dulaglutide terminal elimination half-life was 5 days.

    In plain wordsIn people with diabetes and healthy people, dulaglutide had a terminal half-life of 5 days.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableTerminal elimination half-life
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    Terminal elimination half-life
    5 days
    dulaglutide

    Source sentences

    Summary
    Dulaglutide gradually reached the maximum concentration in 48 h and had a terminal elimination half-life of 5 days.
    1 context sentence
    Summary · context
    The clinical pharmacokinetics of dulaglutide were characterized in patients with T2D and healthy subjects.MethodsThe pharmacokinetics of dulaglutide were assessed throughout clinical development, including conventional pharmacokinetic analysis in clinical pharmacology studies and population…
  3. 03HumanNon-randomized trialPharmacokinetics

    In the clinical pharmacokinetic analysis, dulaglutide reached steady state between the second and fourth doses.

    In plain wordsIn the clinical analysis, dulaglutide reached stable concentrations between the second and fourth doses.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableSteady state
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    Dose number at steady state
    2 to 4 doses
    dulaglutide

    Source sentences

    Summary
    Steady state was achieved between the second and fourth doses.
    1 context sentence
    Summary · context
    The clinical pharmacokinetics of dulaglutide were characterized in patients with T2D and healthy subjects.MethodsThe pharmacokinetics of dulaglutide were assessed throughout clinical development, including conventional pharmacokinetic analysis in clinical pharmacology studies and population…
  4. 04HumanNon-randomized trialPharmacokinetics

    In the clinical pharmacokinetic analysis, dulaglutide accumulation ratio was 1.56 for the 1.5 mg dose.

    In plain wordsIn the clinical analysis, dulaglutide had an accumulation ratio of 1.56 at the 1.5 mg dose.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableAccumulation ratio
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1.5 mg · subcutaneousAs given in this study (human).

    Measurements

    Accumulation ratio
    1.56 ratio
    1.5 mg dose

    Source sentences

    Summary
    The accumulation ratio was 1.56 for the 1.5 mg dose.
    1 context sentence
    Summary · context
    The clinical pharmacokinetics of dulaglutide were characterized in patients with T2D and healthy subjects.MethodsThe pharmacokinetics of dulaglutide were assessed throughout clinical development, including conventional pharmacokinetic analysis in clinical pharmacology studies and population…
  5. 05HumanNon-randomized trialPharmacokinetics

    In the clinical pharmacokinetic analysis, dulaglutide AUC intra-individual variability was below 17% CV.

    In plain wordsIn the clinical analysis, within-person variability in dulaglutide exposure was below 17%.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableWithin-person AUC variability
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    AUC intra-individual variability
    < 17 % CV
    dulaglutide

    Source sentences

    Summary
    Intra-individual variability estimates for the area under the plasma concentration-time curve and the maximum concentration were both <17% [coefficient of variation (CV)].
    1 context sentence
    Summary · context
    The clinical pharmacokinetics of dulaglutide were characterized in patients with T2D and healthy subjects.MethodsThe pharmacokinetics of dulaglutide were assessed throughout clinical development, including conventional pharmacokinetic analysis in clinical pharmacology studies and population…
  6. 06HumanNon-randomized trialPharmacokinetics

    In the clinical pharmacokinetic analysis, dulaglutide maximum concentration intra-individual variability was below 17% CV.

    In plain wordsIn the clinical analysis, within-person variability in peak dulaglutide concentration was below 17%.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableWithin-person maximum concentration variability
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    Cmax intra-individual variability
    < 17 % CV
    dulaglutide

    Source sentences

    Summary
    Intra-individual variability estimates for the area under the plasma concentration-time curve and the maximum concentration were both <17% [coefficient of variation (CV)].
    1 context sentence
    Summary · context
    The clinical pharmacokinetics of dulaglutide were characterized in patients with T2D and healthy subjects.MethodsThe pharmacokinetics of dulaglutide were assessed throughout clinical development, including conventional pharmacokinetic analysis in clinical pharmacology studies and population…
  7. 07HumanNon-randomized trialPharmacokinetics

    In clinical data, a two-compartment model with first-order absorption and elimination described dulaglutide pharmacokinetics well.

    In plain wordsA two-compartment model described dulaglutide concentrations well in the clinical data.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicablePharmacokinetic model fit
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Dulaglutide pharmacokinetics were well described by a two-compartment model with first-order absorption and elimination.
    1 context sentence
    Summary · context
    The clinical pharmacokinetics of dulaglutide were characterized in patients with T2D and healthy subjects.MethodsThe pharmacokinetics of dulaglutide were assessed throughout clinical development, including conventional pharmacokinetic analysis in clinical pharmacology studies and population…
  8. 08HumanNon-randomized trialPharmacokinetics

    In the clinical analysis, dulaglutide population clearance was 0.126 L/h, with inter-individual variability of 33.8% CV.

    In plain wordsIn the clinical analysis, estimated dulaglutide clearance was 0.126 liters per hour.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicablePopulation clearance
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    Population clearance
    0.126 L/h
    dulaglutide
    Inter-individual variability of clearance
    33.8 % CV
    dulaglutide

    Source sentences

    Summary
    The population clearance was estimated at 0.126 L/h [inter-individual variability (CV) 33.8%].
    1 context sentence
    Summary · context
    The clinical pharmacokinetics of dulaglutide were characterized in patients with T2D and healthy subjects.MethodsThe pharmacokinetics of dulaglutide were assessed throughout clinical development, including conventional pharmacokinetic analysis in clinical pharmacology studies and population…

Studies that did not test the peptide alone2

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 09HumanNot a test of Dulaglutide (Trulicity) aloneNon-randomized trialPharmacokinetics

    In the clinical analysis, dulaglutide pharmacokinetics did not differ between arm, thigh and abdomen injection sites.

    In plain wordsIn the clinical analysis, dulaglutide behavior in the body did not differ between arm, thigh and abdomen injections.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeInjection site effect on pharmacokinetics
    Study

    n: not reported in source

    Comparator
    Arm, thigh or abdomen injection sites
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    There was no difference in pharmacokinetics between injection sites (arm, thigh or abdomen).
    1 context sentence
    Summary · context
    The clinical pharmacokinetics of dulaglutide were characterized in patients with T2D and healthy subjects.MethodsThe pharmacokinetics of dulaglutide were assessed throughout clinical development, including conventional pharmacokinetic analysis in clinical pharmacology studies and population…

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 10HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyPharmacokinetics

    In the clinical analysis, age, body weight, sex, race and ethnicity did not influence dulaglutide pharmacokinetics to a clinically relevant degree.

    In plain wordsIn the clinical analysis, demographic characteristics did not meaningfully change dulaglutide behavior in the body.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeDemographic covariate effects
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Age, body weight, sex, race and ethnicity did not influence dulaglutide pharmacokinetics to any clinically relevant degree.
    1 context sentence
    Summary · context
    The clinical pharmacokinetics of dulaglutide were characterized in patients with T2D and healthy subjects.MethodsThe pharmacokinetics of dulaglutide were assessed throughout clinical development, including conventional pharmacokinetic analysis in clinical pharmacology studies and population…

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT05459285

A Pharmacokinetic Study Comparing the 14028 Injection and TRULICITY® in Healthy Chinese Subjects

Sunshine Lake Pharma Co., Ltd.n = 6831 May 2022 to 8 Jul 2022

Type 2 Diabetes

Trial pageClinicalTrials.govUpdated 25 Aug 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.